The company, Molecular Partners AG, is focused on discovering, developing, and commercializing biopharmaceutical products, specifically DARPin® therapeutics, for the treatment of serious diseases such as cancer and sight-threatening disorders. Their product pipeline is organized into three areas: Ophthalmology, Oncology, and Immuno-oncology. Molecular Partners conducts both internal and partnership research and development and has a focus on immuno-oncology and infectious disease. They have compounds in various stages of clinical and preclinical development and are backed by top biotech investors.